CMMB:NASDAQ, Chemomab Therapeutics Ltd.

CMMB stock overview

Chemomab Therapeutics Ltd. (CMMB:NASDAQ) closed at $1.62 on November 16, 2026, up 5.88% on the day. The stock trades 45.8% below its 52-week high of $2.99 and 76.1% above its 52-week low of $0.920. Over the past year, it lost 40.7%. Chemomab Therapeutics Ltd. is part of the Health Care sector.

Key figures

Price
$1.62
Day change
+5.88%
Volume
70,068
Average volume
101,414
Market cap
13M+
52-week range
$0.920 – $2.99
50-day average
$1.65
200-day average
$1.74

Price action over the past year

In 252 trading sessions since November 14, 2025, CMMB closed higher on 114 days (45%). Its best day was July 2, 2026 (+33.53%) and its worst was July 8, 2026 (-28.88%). The stock moved 10% or more in a single session 13 times. It opened at least 5% above the previous day's high 3 times.

Recent signals

CMMB news

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Similar stocks

Find more stocks like CMMB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.